ACRE has launched a new customer portal designed to give aesthetic clinics a simpler way to manage orders and stock, while introducing the foundations for improved product traceability and regulatory compliance.
Built for medical professionals working with pharmaceuticals and medical devices, the portal provides a single, easy-to-use interface to view purchasing history, monitor stock, and streamline day-to-day account management. The portal also provides visibility to help clinics stay aligned with manufacturer commercial policies and maximise available benefits.
While the current version focuses on commercial visibility, the platform is underpinned by ACRE’s existing ability to track batch and expiry data, enabling clinics to access key product information in one place and move towards more robust record-keeping.
As regulatory expectations continue to evolve across the aesthetics sector, the ability to evidence where products were sourced, and how they are used, is becoming increasingly important.
“Clinics will need to know exactly what product, batch and expiry went into every patient’s treatment,” said Bob Melville, ACRE Director.
“This portal is designed to make that level of traceability far more accessible in day-to-day practice.”
Future releases will introduce enhanced compliance tools, including inspection-readiness guidance, structured batch and expiry tracking, and the ability to support more complete treatment documentation over time.
ACRE also plans to introduce an embedded AI assistant within the platform, designed to help clinics access key information quickly and support operational tasks across stock management, procurement, and business performance.
Unlike many existing systems, the portal is designed to work alongside clinics’ current workflows, integrating with existing processes rather than replacing them.
“Today’s launch is just the starting point,” Neil Clarkson, ACRE Director added.
“Our focus is on building a platform that not only simplifies ordering, but helps clinics become and stay inspection-ready as the industry moves towards greater regulation.”